Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Sarcoidosis.

Robert P Baughman1, Elyse E Lower, Roland M du Bois

  • 1Department of Internal Medicine, University of Cincinnati, Cincinnati Medical Center, Cincinnati, OH 45267-0565, USA. bob.baughman@uc.edu

Lancet (London, England)
|April 4, 2003
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Bridging the Gap: The Emerging Role of memory CD8+ T Cells in Fibrotic Interstitial Lung Disease.

American journal of respiratory cell and molecular biology·2026
Same author

Prevalence of relapse in pulmonary sarcoidosis: A systematic review and meta-analysis.

Respiratory medicine·2026
Same author

Safety and efficacy of namilumab for the treatment of chronic pulmonary sarcoidosis (RESOLVE-Lung): A randomized, double-blinded, multicenter, Phase 2 study.

The European respiratory journal·2026
Same author

Incidence of New Comorbidities After Steroid Use in Patients With Sarcoidosis: An International Cross-Sectional Survey.

Chest·2025
Same author

A paradigm shift in corticosteroid therapy for sarcoidosis: a World Association of Sarcoidosis and Other Granulomatous Disorders Position Paper, endorsed by the Americas Association of Sarcoidosis and Other Granulomatous Disorders.

The Lancet. Respiratory medicine·2025
Same author

WASOG Clinical Trial Endpoint Task Force: Executive Summary.

Sarcoidosis, vasculitis, and diffuse lung diseases : official journal of WASOG·2025
Same journal

Rethinking anticoagulation intensity during extracorporeal membrane oxygenation.

Lancet (London, England)·2026
Same journal

Standard-dose unfractionated heparin versus low-dose unfractionated heparin and low-molecular-weight heparin in extracorporeal life support (RATE): an open-label, randomised, non-inferiority trial.

Lancet (London, England)·2026
Same journal

Inherited retinal degenerations: clinical phenotypes and emerging therapies.

Lancet (London, England)·2026
Same journal

Documenting hospice care.

Lancet (London, England)·2026
Same journal

After the wood chipper.

Lancet (London, England)·2026
Same journal

Assisted dying and the silencing of medicine's next generation.

Lancet (London, England)·2026
See all related articles

Genetic variations and ethnic origin influence sarcoidosis risk and presentation. New treatments targeting tumour necrosis factor (TNF) offer steroid-sparing options for chronic sarcoidosis.

Area of Science:

  • Immunology
  • Genetics
  • Pulmonology

Background:

  • Sarcoidosis is an inflammatory disease with complex etiology.
  • Genetic factors, including polymorphisms in MHC and cytokines like tumor necrosis factor (TNF), are implicated in sarcoidosis risk and disease presentation.
  • Patient's ethnic origin may interact with genetic factors, influencing disease outcomes.

Purpose of the Study:

  • To review recent insights into the genetic basis of sarcoidosis.
  • To discuss current and emerging treatment strategies for sarcoidosis, particularly for chronic symptomatic disease.
  • To highlight the role of TNF-blocking agents in managing sarcoidosis.

Main Methods:

  • Review of genetic association studies identifying polymorphisms linked to sarcoidosis.

Related Experiment Videos

  • Analysis of treatment data for symptomatic sarcoidosis, focusing on corticosteroid use and steroid-sparing agents.
  • Evaluation of novel therapeutic agents, including pentoxifylline, thalidomide, and infliximab, for their efficacy in sarcoidosis.

    • Main Results:

    • Specific genetic polymorphisms (e.g., in MHC, TNF) are associated with sarcoidosis susceptibility and presentation.
    • Corticosteroids remain a primary treatment for symptomatic sarcoidosis, but immunosuppressive drugs offer steroid-sparing benefits.
    • Newer agents like infliximab, which block TNF, show promise in selected chronic sarcoidosis cases.

    Conclusions:

    • Sarcoidosis pathogenesis involves a complex interplay of genetic predisposition, ethnic background, and environmental factors.
    • Effective management of chronic sarcoidosis may require personalized treatment approaches.
    • Targeting TNF with agents like infliximab represents a significant advancement in treating refractory sarcoidosis.